Short Interest in Celularity Inc. (NASDAQ:CELU) Rises By 50.0%

Celularity Inc. (NASDAQ:CELU) was the target of a significant growth in short interest in the month of March. As of March 15th, there was short interest totalling 1,560,000 shares, a growth of 50.0% from the February 28th total of 1,040,000 shares. Based on an average daily volume of 159,900 shares, the short-interest ratio is currently 9.8 days. Approximately 11.9% of the shares of the company are sold short.

Celularity Stock Performance

CELU traded down $0.03 during midday trading on Monday, reaching $1.75. The company had a trading volume of 11,516 shares, compared to its average volume of 327,232. The business has a 50-day moving average of $1.84 and a two-hundred day moving average of $2.22. Celularity has a 1 year low of $1.00 and a 1 year high of $5.69.

Institutional Investors Weigh In On Celularity

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Keynote Financial Services LLC boosted its position in shares of Celularity by 90.1% in the fourth quarter. Keynote Financial Services LLC now owns 25,023 shares of the company’s stock worth $52,000 after purchasing an additional 11,863 shares during the period. Biltmore Family Office LLC bought a new position in Celularity in the 4th quarter worth $73,000. Two Sigma Investments LP purchased a new stake in Celularity in the 4th quarter worth $93,000. Finally, C V Starr & Co. Inc. purchased a new stake in Celularity in the 4th quarter worth $1,589,000. 19.02% of the stock is owned by hedge funds and other institutional investors.

Celularity Company Profile

Celularity Inc, a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease.